• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Low-dose intravitreal triamcinolone lowers incidence of steroid-induced glaucoma

Article

Two large prospective studies are under way to define better the ideal dose for IVTA injections.

Jeffrey D. Benner, MD, clinical professor of ophthalmology at the University of Maryland School of Medicine and a partner in the Retina Consultants of Delmarva, decided to explore the lower dose of IVTA after one of his patients developed severe glaucoma following an intravitreal injection of 4 mg of triamcinolone acetonide.

Injecting triamcinolone acetonide into the vitreous has emerged as a promising treatment for diabetic macular edema and other conditions that cause macular edema. The most frequent complication associated with IVTA has been elevation of the IOP. The incidence of steroid-induced elevation of the IOP after IVTA as reported in the literature ranges from a low of 25% (4 mg)1 to a high of 52% (25 mg).2

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.